As such, monoclonal antibodies targeting interleukin-1 beta (IL-1β) in the CANTOS trial resulted in lower cardiovascular events, however total mortality was unaffected due to severe leukopenia and subsequent sepsis [10]. This evidence concerns the gene IL1B and Decreased total leukocyte count.